We are live on ! Find out more
DSGN icon

Design Therapeutics

96 hedge funds and large institutions have $223M invested in Design Therapeutics in 2023 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 23 increasing their positions, 27 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

286% more call options, than puts

Call options by funds: $1.09M | Put options by funds: $283K

68% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 19

16% more funds holding

Funds holding: 8396 (+13)

3.04% less ownership

Funds ownership: 72.2%69.17% (-3%)

15% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 27

46% less capital invested

Capital invested by funds: $413M → $223M (-$189M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
96
Holders Change
+13
Holders Change %
+15.66%
% of All Funds
1.53%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
32
Increased
23
Reduced
27
Closed
19
Calls
$1.09M
Puts
$283K
Net Calls
+$808K
Net Calls Change
-$3.78M

DSGN Hedge Fund Activity: Q1 2023 in Review

96 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q1 2023, worth a combined $223M — down 46% from $413M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new DSGN positions and 19 closed out — a net gain of 13 holders — while 23 added to existing stakes and 27 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $9.18M. The largest seller was State Street, cutting an estimated $17.4M.

  • 96 institutional investors held Design Therapeutics (DSGN) as of Q1 2023, up from 83 in Q4 2022.
  • Funds reported $223M of Design Therapeutics stock for Q1 2023, down 46% quarter-over-quarter.
  • 32 funds opened new Design Therapeutics positions in Q1 2023 and 19 closed out, a net change of +13 holders.
  • The largest Design Therapeutics buyer in Q1 2023 was Avoro Capital Advisors, an estimated $9.18M added.
  • The largest Design Therapeutics seller in Q1 2023 was State Street, an estimated $17.4M sold.

Based on aggregated 13F filings for Q1 2023.